NASDAQ: INCY · Biotechnology
Incyte (INCY) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Incyte (INCY) at $136.90 a share. The stock last closed at $120.27, which puts the model's fair value 13.8% above the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Incyte Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $126.15 to $136.90 (+8.5%). The model shifted weight between the company's own multiple and its peers': most of the move.
What the model makes of itThe price of $120.27 is 13.8% below it: Fairly valued, on a medium evidence grade.
What's nextNext report on 9 Feb 2027. Options prices imply a move of about 16% either way over the next month. On the model's Scorecard Leaders list since 3 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give INCY?
The calibrated range for INCY over 63 trading days is $100.57 to $145.14. It sits around the last close, and its width comes from the volatility that INCY's own options imply (54% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $101.10 to $184.84. In 63% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Incyte Corporation (INCY) is a biopharmaceutical firm in the Healthcare sector, Biotechnology industry. It is engaged in the research, development, and global marketing of its own innovative therapies.
Faircurve's model put the fair value at $136.90 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $126.15, so the fair value moved +8.5%. The model's own words on the move: "The model shifted weight between the company's own multiple and its peers': most of the move." The calibrated range over 63 trading days is $104.56 to $140.99, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence Medium. The grade covers input completeness, comparable count and agreement, and outcome spread. It does not say whether the fair value is right.
Incyte's overall quality score is 71 out of 100 against comparable companies. Balance sheet scores 100, with net debt / EBITDA of -3.71x against a peer median of -0.07x. Earnings quality scores 79, with FCF / net income of 1.70x against a peer median of 1.19x. Capital discipline scores 41, with net buybacks / market value of 0.0% against a peer median of 3.0%. The model compares the company with United Therapeutics Corporation (UTHR), Roivant Sciences Ltd. (ROIV), Neurocrine Biosciences, Inc. (NBIX) and Bio-Techne Corporation (TECH).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does INCY report earnings, and how has the stock reacted?
Incyte's next earnings report is scheduled for 9 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 12.6% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. INCY's 30 day implied volatility works out to about 15.7% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across INCY's last 8 reports, ignoring direction, was 4.4%.
What the options market has priced for a month's move in INCY
How does INCY score on business quality?
Incyte's overall quality score is 71 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 74 | 18.9%ROIC | 14.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 79 | 1.70xFCF / net income | 1.19x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 73 | 21.2%Revenue growth, trailing | 7.0% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 41 | 0.0%Net buybacks / market value | 3.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | -3.71xNet debt / EBITDA | -0.07x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 39 | 5.6 ptsEBITDA margin downside volatility, 5y | 4.7 pts |
How does INCY compare with similar companies?
The companies in biotechnology closest to Incyte in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| UTHR United Therapeutics Corporation | $587.88 | $601.98 | +2.4% | Fairly valued |
| INSM Insmed Incorporated | $122.88 | $113.05 | -8.0% | Low evidence grade |
| ALNY Alnylam Pharmaceuticals, Inc. | $159.73 | $165.54 | +3.6% | Low evidence grade |
| ROIV Roivant Sciences Ltd. | $38.61 | $26.96 | -30.2% | Overvalued |
| EXEL Exelixis, Inc. | $67.10 | $68.00 | +1.3% | Low evidence grade |
| NBIX Neurocrine Biosciences, Inc. | $165.31 | $171.92 | +4.0% | Fairly valued |
| JAZZ Jazz Pharmaceuticals plc | $239.77 | $288.09 | +20.2% | Low evidence grade |
| TECH Bio-Techne Corporation | $72.79 | $65.76 | -9.7% | Fairly valued |
What the comparable companies' multiples alone would give for INCY, the peer-implied price, is $182.81 a share on this run. The fair value weighs that against the company's own multiple.
Incyte at a glance
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies.
- Market value
- $24.7B
- Sector
- Healthcare
- Industry
- Biotechnology
- Revenue expected, next twelve months
- $6.2B
- Consensus revenue growth, next fiscal year
- +17.6%
- Analysts with estimates
- 14
- Beta to the US market
- 0.31
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. INCY was among them.
How the fair value is worked out: the model prices Incyte on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for INCY was $126.15. As of 14 Nov 2026 it is $136.90, a change of +8.5%. The model shifted weight between the company's own multiple and its peers': most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Incyte's valuation
Is Incyte stock undervalued or overvalued?
On Faircurve's model, INCY reads as Fairly valued as of 14 Nov 2026. The model's fair value is $136.90 a share against a last close of $120.27, a gap of +13.8%.
What is INCY's fair value?
$136.90 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $101.10 to $184.84.
What price range does the model give INCY?
$100.57 to $145.14 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Incyte report earnings next?
The next report is scheduled for 9 Feb 2027. Companies can move their dates.
How much has INCY moved on past earnings reports?
Across its last 8 reports the median two session move was 4.4%, ignoring direction. The largest was +10.5% around the report of 29 Jul 2025.
How confident is the model in this valuation?
The model's evidence grade for INCY is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on INCY
The model has an idea open on INCY under Scorecard Leaders since 3 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on INCY with their outcomes. A free account is enough.